Innovative Technology Focus Immuneed's proprietary ID.Flow technology emphasizes the use of human blood to enhance drug safety assessments, representing an innovative approach that appeals to biotech firms seeking more accurate preclinical testing solutions.
Recent Asset Sale The company's sale of its immunotherapy technology assets to Ultimovacs indicates a strategic shift or potential openness to partnerships, signaling opportunities for collaboration with firms interested in specialized immunotherapy platforms.
Funding and Growth Potential With a recent funding of over half a million dollars and a focus on research services, Immuneed is positioned for targeted growth and may benefit from partnerships with larger players looking to capitalize on innovative preclinical testing technologies.
Industry Niche & Market Entry Operating within a specialized segment of research services in Sweden, Immuneed offers potential entry points for global biotech and pharma companies aiming to incorporate more human-relevant testing methodologies into their development pipelines.
Limited Revenue but Potential Although current revenue is modest, the company's technological innovations and recent asset sale create opportunities for business development teams to explore licensing, collaborations, or expansion into related preclinical testing markets.
$250M$500M
$1M$10M
$1B$10B
$1M
$10B
$1B$10BImmuneed uses 8 technology products and services including Amazon Web Services, Cybot, Webpack, and more. Explore Immuneed's tech stack below.
| Immuneed Email Formats | Percentage |
| First.Last@immuneed.com | 48% |
| First.Middle@immuneed.com | 2% |
| First.Last@immuneed.com | 48% |
| First.Middle@immuneed.com | 2% |
Research ServicesUppsala, Sweden11-50 Employees
Our technology, ID.Flow, utilizes freshly donated human blood to help researchers better understand drug-induced immune reactions during non-clinical development. By improving the accuracy and relevance of safety and efficacy assessments, we reduce the need for animal studies and enhance the translatability of preclinical findings.
Company Overview
Funding & FinancialsImmuneed has raised a total of $504K of funding over 1 rounds. Their latest funding round was raised on Sep 13, 2016 in the amount of $504K.
Immuneed's revenue is estimated to be in the range of $1M
Funding & FinancialsImmuneed has raised a total of $504K of funding over 1 rounds. Their latest funding round was raised on Sep 13, 2016 in the amount of $504K.
Immuneed's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com